---
title: "Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286193404.md"
description: "Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News"
datetime: "2026-05-12T20:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286193404.md)
  - [en](https://longbridge.com/en/news/286193404.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286193404.md)
---

# Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News

Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes | MIRM Stock News

### Related Stocks

- [MIRM.US](https://longbridge.com/en/quote/MIRM.US.md)

## Related News & Research

- [Assessing Mirum Pharmaceuticals (MIRM) Valuation After A Strong Year And Recent Share Price Pullback](https://longbridge.com/en/news/286635606.md)
- [BUZZ-Mirum Pharma drops on announcing $600 mln convertible debt deal](https://longbridge.com/en/news/286150832.md)
- [This Interface Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday](https://longbridge.com/en/news/286923370.md)
- [Mirum Pharmaceuticals Announces Primary Endpoint Met In Phase 2B Portion Of The Azure-1 Study](https://longbridge.com/en/news/284218464.md)
- [Mirum Pharmaceuticals Announces Primary Endpoint Met In Vistas Study Of Volixibat In Patients With Primary Sclerosing Cholangitis](https://longbridge.com/en/news/285068642.md)